An adaptive medical treatment decision system for targeted cancer therapy, comprising: a medical experience register, the medical experience register storing medical experience data from a plurality of users, wherein the medical experience data from each user is encoded and includes anonymous, patient-specific physical, biological and clinical data and; a clinical evidence register, the clinical evidence register storing result data from at least a subset of the plurality of users, the result data including anonymous molecular and clinical profiles of respective prior patients, diagnoses of the respective prior patients, treatments administered to the respective prior patients, the molecular variations found in the patient's cancer, frequency of genetic variations, drug targets, and outcomes of the treatments administered to the respective prior patients in association with specific genetic alterations; a processor connected to the medical experience register and the clinical evidence register for requesting and receiving signals from the medical experience register and the clinical evidence register, the processor enabled to process said received signals to rank treatment options based on a specific patient physical, biological or clinical profile and diagnosis and frequency of genetic variations stored in the clinical evidence register, wherein, in the therapy of cancer, targeted therapies are ranked based on their response in previously treated patients similar to the present patient, wherein the ranking prefers the experience associated with a targeted therapy with patients with the same driver genetic alterations selected from the group comprising point mutation, copy number variations, translocations; and if there is no experience yet with the exactly same driver genetic alterations, the targeted therapies are ranked based on the clinical results in patients with alterations in the same driver genes, and if there is no experience yet with the exactly same driver genes, experience with driver genes in the same signal transduction pathway, therefore the same molecular targets, is considered, and if there is no experience yet with the same targets, the ranking is based on the tumor type; wherein said patient is to be treated based on this ranking and the clinical response is registered in the system to add to the experience database. a medical experience register, the medical experience register storing medical experience data from a plurality of users, wherein the medical experience data from each user is encoded and includes anonymous, patient-specific physical, biological and clinical data and; a clinical evidence register, the clinical evidence register storing result data from at least a subset of the plurality of users, the result data including anonymous molecular and clinical profiles of respective prior patients, diagnoses of the respective prior patients, treatments administered to the respective prior patients, the molecular variations found in the patient's cancer, frequency of genetic variations, drug targets, and outcomes of the treatments administered to the respective prior patients in association with specific genetic alterations; a processor connected to the medical experience register and the clinical evidence register for requesting and receiving signals from the medical experience register and the clinical evidence register, the processor enabled to process said received signals to rank treatment options based on a specific patient physical, biological or clinical profile and diagnosis and frequency of genetic variations stored in the clinical evidence register, wherein, in the therapy of cancer, targeted therapies are ranked based on their response in previously treated patients similar to the present patient, wherein the ranking prefers the experience associated with a targeted therapy with patients with the same driver genetic alterations selected from the group comprising point mutation, copy number variations, translocations; and if there is no experience yet with the exactly same driver genetic alterations, the targeted therapies are ranked based on the clinical results in patients with alterations in the same driver genes, and if there is no experience yet with the exactly same driver genes, experience with driver genes in the same signal transduction pathway, therefore the same molecular targets, is considered, and if there is no experience yet with the same targets, the ranking is based on the tumor type;